Molecular Mechanisms of Antifungal Drug Resistance

Resistance to clinical antifungal agents has emerged as a critical threat to global health, driven by adaptive changes at the molecular level in diverse fungal pathogens. Primary classes of antifungals—including azoles, echinocandins, polyenes and nucleic acid inhibitors—target key components of cell membrane integrity, cell wall biosynthesis and nucleic acid metabolism. Molecular mechanisms underpinning resistance span alterations in drug targets, enhanced efflux, modulation of stress-response pathways and large-scale genome rearrangements. Point mutations in sterol 14α-demethylase reduce azole binding, while substitutions in glucan synthase subunits compromise echinocandin efficacy. Overexpression of ATP-binding cassette and major facilitator superfamily transporters lowers intracellular drug concentrations. The molecular chaperone Hsp90 and its client calcineurin orchestrate stress responses that buffer the impact of membrane or cell-wall perturbation, often converting fungistatic agents into fungicidal combinations. Adaptive genome plasticity—including aneuploidy, loss of heterozygosity and copy-number variation—facilitates rapid evolution under drug pressure, driving multidrug resistance and treatment failure. Biofilm formation further augments resistance through extracellular matrix sequestration of drugs and altered growth states. Together, these interconnected strategies demonstrate how fungi exploit native biosynthetic and regulatory networks to circumvent pharmacological inhibition and underscore the urgent need for selective inhibitors and combination therapies that target resistance-enabling circuitry.

Research from Nature Portfolio

Recent studies have revealed that in Aspergillus fumigatus, inhibition of sterol 14α-demethylase by azoles leads to the accumulation of the demethylase substrate eburicol. This build-up triggers the formation of lethal carbohydrate patches in the fungal cell wall, identifying eburicol accumulation as a fungicidal mechanism distinct from the classical toxic-diol pathway. Insights into sterol pathway flux and enzyme-specific contributions have opened new avenues for enhancing azole potency. In parallel, high-resolution structures of the nucleotide-binding domain of Hsp90 from Candida albicans have disclosed unique conformational states not present in human Hsp90. Structure-guided design of a fungal-selective inhibitor demonstrated over 25-fold binding selectivity, laying the foundation for species-targeted disruption of stress response signalling without host toxicity.

Molecular Mechanisms of Antifungal Drug Resistance publication trend

The graph below shows the total number of articles in molecular mechanisms of antifungal drug resistance across all publications each year (not limited to Nature Index journals).

Technical terms

Azoles: A class of antifungals that inhibit sterol 14α-demethylase, disrupting ergosterol biosynthesis and compromising membrane integrity.

Eburicol: The substrate of sterol 14α-demethylase whose intracellular accumulation under azole treatment induces fungicidal cell-wall alterations in filamentous fungi.

Efflux pump: Transmembrane transporter proteins that expel antifungal agents from the cell, reducing intracellular drug concentration and efficacy.

Ergosterol biosynthesis: The pathway by which fungi produce ergosterol, a key membrane sterol; perturbation of this pathway is the target of multiple drug classes.

Hsp90: A molecular chaperone that stabilises client proteins involved in stress signalling (such as calcineurin), critical for antifungal tolerance and resistance.

References

1. Toxic eburicol accumulation drives the antifungal activity of azoles against Aspergillus fumigatus. Nature Communications (2024).
2. Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus. Nature Communications (2019).
3. Pol32, an accessory subunit of DNA polymerase delta, plays an essential role in genome stability and pathogenesis of Candida albicans. Gut Microbes (2023).
4. Candidiasis and Mechanisms of Antifungal Resistance. Antibiotics (2020).
5. Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin. PLOS Pathogens (2009).